Compare ANGO & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANGO | SPXX |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 340.5M |
| IPO Year | 2004 | 2005 |
| Metric | ANGO | SPXX |
|---|---|---|
| Price | $11.26 | $18.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.75 | N/A |
| AVG Volume (30 Days) | ★ 921.2K | 232.3K |
| Earning Date | 10-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $291,010,000.00 | N/A |
| Revenue This Year | $5.47 | N/A |
| Revenue Next Year | $5.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $9.39 | $15.78 |
| 52 Week High | $16.29 | $19.39 |
| Indicator | ANGO | SPXX |
|---|---|---|
| Relative Strength Index (RSI) | 26.29 | 43.11 |
| Support Level | $10.21 | $18.23 |
| Resistance Level | $11.55 | $18.53 |
| Average True Range (ATR) | 0.83 | 0.24 |
| MACD | -0.36 | 0.00 |
| Stochastic Oscillator | 9.92 | 31.17 |
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on approximately 35% to 75% of the notional value of the Fund's equity portfolio in an effort to enhance the Fund's risk-adjusted returns.